Innovative approach to prediction and therapy of preeclampsia: global experience

1. Meiri H., Osol G., Cetin I., Gizurarson S., Huppertz B. Personalized therapy against pre-eclampsia by replenishing placental protein 13 (PP13) targeted to patients with impaired PP13 molecule or function. Comput. Struct. Biotechnol. J. 2017; 15: 433-46.
2. Backes C.H., Markham K., Moorehead P., Cordero L., Nankervis C.A., Giannone P.J. Maternal pre-eclampsia and neonatal outcomes. J. Pregnancy. 2011; 2011: 214365.
3. NICE. National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). Diagnostics guidance [DG23]. May, 2016.
4. Osol G., Bernstein I. Pre-eclampsia and maternal cardiovascular disease: consequence or predisposition? J. Vasc. Res. 2014; 51(4): 290-304.
5. Uzan J., Carbonnel M., Piconne O., Asmar R., Ayoubi J.M. Pre-elampsia: Pathophysiology, diagnosis, and management. Vasc. Health Risk Manag. 2011; 7: 467-74.
6. Cerdeira A.S., Agrawal S., Staff A.C., Redman C.W., Vatish M. Angiogenic factors: potential to change clinical practice in pre-eclampsia? BJOG. 2018; 125(11): 1389-95.
7. Zhang J., Klebanoff M.A., Roberts J.M. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet. Gynecol. 2001; 97(2): 261-7.
8. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 2013; 122(5): 1122-31.
9. Tranquilli A.L., Dekker G., Magee L., Roberts J., Sibai B.M., Steyn W. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4(2): 97-104.
10. Холин А.М., Ходжаева З.С., Гус А.И. Патологическая плацентация и прогнозирование преэклампсии и задержки роста плода в первом триместре. Акушерство и гинекология. 2018; 5: 12-9. [Kholin A.M., Khodzhaeva Z.S., Gus A.I. Pathological placentation and prediction of pre-eclampsia and fetal growth retardation in the first trimester. Akusherstvo i Ginekologiya/Obstetrics and gynecology. 2018; 5: 12-9.(in Russian)].
11. Roberts J.M., Bell M.J. If we know so much about preeclampsia, why haven’t we cured the disease? J. Reprod. Immunol. 2013; 99(1-2): 1-9.
12. Myatt L., Clifton R.G., Roberts J.M., Spong C.Y., Hauth J.C., Varner M.W. et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet. Gynecol. 2012; 119(6): 1234-42.
13. Staff A.C., Benton S.J., von Dadelszen P., Roberts J.M., Taylor R.N., Powers R.W. et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013; 61(5): 932-42.
14. Kaitu‘u-Lino T.J., Brownfoot F.C., Beard S., Cannon P., Hastie R., Nguyen T.V. et al. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating pre-eclampsia. PLoS One. 2018; 13(2): e0188845.
15. Schmella M.J., Roberts J.M., Conley Y.P., Ren D., Storvold G.L., Ingles S.A. et al. Endoglin pathway genetic variation in pre-eclampsia: A validation study in Norwegian and Latina cohorts. Pregnancy Hypertens.2018; 12: 144-9.
16. Herraiz I., Simón E., Gómez-Arriaga P.I., MartínezMoratalla J.M., García-Burguillo A., Jiménez E.A. et al. Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: an approach for clinical integration. Int. J. Mol. Sci. 2015; 16(8): 19009-26.
17. Lecarpentier E., Tsatsaris V. Angiogenic balance (sFlt1/ PlGF) and pre-eclampsia. Ann. Endocrinol. (Paris). 2016; 77(2): 97-100.
18. Gurnadi J.I., Mose J., Handono B., Satari M.H., Anwar A.D., Fauziah P.N. et al. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1:PlGF ratio in severe pre-eclampsia and normal pregnancy. BMC Res. Notes.2015; 8: 534.
19. Mutter W.P., Karumanchi S.A. Molecular mechanisms of preeclampsia. Microvasc. Res. 2008; 75(1): 1-8.
20. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355(10):992-1005.
21. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Moertl M., Zeisler H. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 2012; 206(1): 58. e1-8.
22. Bramham K., Seed P.T., Lightstone L., Nelson-Piercy C., Gill C., Webster P. et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int. 2016; 89(4): 874-85.
23. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected pre-eclampsia. N. Engl. J. Med. 2016; 374(1): 13-22.
24. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M. et al. Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected pre-eclampsia. Obstet. Gynecol. 2016; 128(2): 261-9.
25. Klein E., Schlembach D., Ramoni A., Langer E., Bahlmann F., Grill S. et al. Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected pre-eclampsia. PLoS One. 2016; 11(5): e0156013.
26. Rana S., Schnettler W.T., Powe C., Wenger J., Salahuddin S., Cerdeira A.S. et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens. Pregnancy. 2013; 32(2): 189-201.
27. Schoofs K., Grittner U., Engels T., Pape J., Denk B., Henrich W. et al. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of pre-eclampsia and intrauterine growth restriction. J. Perinat. Med. 2014;42: 61-8.
28. Goel A., Maski M.R., Bajracharya S., Wenger J.B., Zhang D., Salahuddin S. et al. Epidemiology and mechanisms of De Novo and persistent hypertension in the postpartum period. Circulation. 2015; 132(18):1726-33.
29. Committee Opinion No. 638: frst-trimester risk assessment for early-onset preeclampsia. Obstet. Gynecol. 2015; 126(3): e25-7.
30. Spradley F.T., Tan A.Y., Joo W.S., Daniels G., Kussie P., Karumanchi S.A. et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension. 2016; 67(4): 740-7.
31. Siddiqui A.H., Irani R.A., Zhang Y., Dai Y., Blackwell S.C., Ramin S.M. et al. Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice. Am. J. Hypertens. 2011; 24(5): 606-12.
32. Gilbert J.S., Verzwyvelt J., Colson D., Arany M., Karumanchi S.A., Granger J.P. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension. 2010; 55(2): 380-5.
33. Makris A., Yeung K.R., Lim S.M., Sunderland N., Heffernan S., Thompson J.F. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension. 2016; 67(6): 1263-72.
34. Thadhani R., Kisner T., Hagmann H., Bossung V., Noack S., Schaarschmidt W. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011; 124(8): 940-50.
35. Thadhani R., Hagmann H., Schaarschmidt W., Roth B., Cingoez T., Karumanchi S.A. et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 2016; 27(3): 903-13.
36. Fox K.A., Longo M., Tamayo E., Kechichian T., Bytautiene E., Hankins G.D. et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase- 1-induced preeclampsia. Am. J. Obstet. Gynecol. 2011; 205(6): 366. e1-5.
37. Kumasawa K., Ikawa M., Kidoya H., Hasuwa H., Saito-Fujita T., Morioka Y. et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc. Natl. Acad. Sci. USA. 2011; 108(4): 1451-5.
38. Costantine M.M., Cleary K.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet. Gynecol. 2013; 121(2, Pt 1): 349-53.
39. Conrad K.P. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin. Nephrol. 2011; 31(1): 15-32.
40. Jiang X., Bar H.Y., Yan J., Jones S., Brannon P.M., West A.A. et al. A higher maternal choline intake among third-trimester pregnant women lowers placental and circulating concentrations of the antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1). FASEB J. 2013; 27(3): 1245-53.

Received 15.02.2019

Accepted 22.02.2019